- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03113123
Prevention of HIV in "Île-de-France" (ANRS-PREVENIR)
Interventional HIV prevention strategy based on pre-exposure prophylaxis (PrEP) with Truvada® for people in the Île-de-France area (or Paris region) who don't have HIV but who are at high risk of becoming infected with HIV (men who have sex with men (MSM), transgender men and women, heterosexual men and women, sex workers, migrants) in combination with overall prevention services (communautary-based or educational counselling; addiction, social and psychological care; condoms and lubricating gel; clean injection equipment; sexually transmitted diseases (STD) screening and treatment; hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) vaccinations and post-exposure treatment of HIV infection as soon as possible after diagnosis using an antiretroviral combination recommended by the French Guidelines on HIV treatment).
The individual benefit being already demonstrated in clinical trials, the aim is to demonstrate the public health impact of the interventional HIV prevention strategy by reducing the risk of getting HIV-1 infection of at least 15% of new diagnosis of HIV infections among MSM/transgender in the Ile-de-France area after a 3-year period.
Study Overview
Detailed Description
Assuming the PrEP efficacy of 80% and that 85% of included participants being MSM - the objective is to evidence a decrease of at least 15% of new diagnosis of HIV infections among MSM in Ile-de-France area. This objective is in the framework of a commitment of large cities against AIDS with the political support of the City of Paris for the "Paris sans SIDA" program and the commitment of the Île-de-France area.
Secondary Objectives:
- Prevalence of HIV infection at the screening visit (undiagnosed epidemic)
- Incidence of HIV infection according to back-calculation approach, and by key subgroups
Operational Objectives:
- Evaluate the origin of the recruitment according to the risk groups and the outreach actions
- Assess linkage to care for PrEP, retention in the study, reasons for consent withdrawal and satisfaction of the participants according to the screening site, the type of PrEP supply, the costs of global care, the key subgroups, the type of counselling, the time from STD testing to initiation of PrEP treatment in study sites
- Impact of a less intense counselling than the one provided in the ANRS IPERGAY trial, on adherence and efficacy of PrEP by comparing the incidence observed in MSM enrolled in the current study to that evidenced in the ANRS IPERGAY trial, with a method similar to that used in the Partner demonstration project in Kenya and Uganda.
- Impact of the communautary-based and educational counselling
Clinical Objectives:
- Estimation, in individuals seeking for PrEP and thus getting tested for HIV infection, the prevalence of HIV infection in different key subgroups, which is a surrogate marker of the undiagnosed (or "hidden") epidemic
- Evaluate who will become HIV-infected during the course of the study while on PrEP, the proportion of patients on combined antiretroviral treatment and the proposition of patients with a suppressed HIV viral load 12 months after HIV infection
- Evaluate the participants' need for post-exposure prophylaxis during the course of the study
- Adherence to PrEP (questionnaire and dried blood spots)
- Assessment of the PrEP dosing schedule used by MSM participants (daily or intermittent) throughout the course of the study
- Assessment of PrEP tolerability and safety
- Comprehensive study of incident HIV infections in those on PrEP (incidence, emergence of drug-associated resistance mutations, adherence to PrEP at the closest visit before HIV seroconversion and at previous visits)
Participants Behavior:
- Acceptability of PrEP (including those who will decline participation in the study) and during the course of the study, and retention in the study.
- Impact of PrEP, within a comprehensive prevention offer, on sexual behavior of the participants throughout follow-up
Factors associated with the integration of PrEP in the daily routine of participants:
- Qualitative study to explore the motivations, difficulties, behavior and expectations of the participants, their knowledge and communication on their use of PrEP
- Reasons related to the choice of the prevention strategy used in terms of dosing schedule (continuous or on demand in MSM) and type of counselling and participation to focus groups.
Care Providers Behavior: Evaluation of knowledge, beliefs, perception and practice of the physicians, nurse and peer counselors involved in delivery of PrEP in the study
Social epidemiology: Evaluation of social and/or territorial inequalities and disparities
Cost-effectiveness of the comprehensive prevention strategy
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jean-Michel MOLINA, Pr
- Phone Number: 0142499066
- Email: jean-michel.molina@aphp.fr
Study Contact Backup
- Name: Jade GHOSN, MD
- Phone Number: 0142348836
- Email: jade.ghosn@aphp.fr
Study Locations
-
-
-
Bobigny, France, 93000
- Completed
- Hôpital Avicenne
-
Bondy, France, 93143
- Completed
- Hôpital Jean Verdier
-
Boulogne, France, 92104
- Completed
- Hôpital Ambroise-Paré
-
Clamart, France, 92141
- Completed
- Hopital Antoine Beclere
-
Colombes, France, 92700
- Completed
- Hôpital Louis Mourier
-
Creteil, France, 94010
- Completed
- Hôpital Henry Mondor
-
Garches, France, 92380
- Completed
- Hôpital Raymond Poincaré
-
Le Kremlin Bicêtre, France, 94275
- Completed
- Hopital de Bicetre
-
Melun, France, 77011
- Completed
- Centre Hospitalier Marc Jacquet
-
Paris, France, 75475
- Recruiting
- Hôpital Saint-Louis
-
Paris, France, 75970
- Recruiting
- Hopital Tenon
-
Paris, France, 75006
- Completed
- Hôpital Cochin
-
Paris, France, 75181
- Completed
- Hôpital Hotel Dieu
-
Paris, France, 75571
- Completed
- Hôpital Saint-Antoine
-
Paris, France, 75641
- Completed
- Hôpital Pitié-Salpêtrière
-
Paris, France, 75651
- Completed
- Hôpital Pitié-Salpêtrière
-
Paris, France, 75743
- Completed
- Hopital Necker-Enfants Malades
-
Paris, France, 75876
- Completed
- Hôpital Bichat-Claude-Bernard
-
Paris, France, 75908
- Completed
- Hôpital européen Georges Pompidou
-
Saint Germain en Laye, France, 78105
- Completed
- Chi Poissy Saint Germain En Laye
-
Suresnes, France, 92151
- Completed
- Hopital Foch
-
Versailles, France, 78157
- Completed
- Hôpital André Mignot
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- Men/transgender men/women who have sex with men, heterosexual men and women, sex workers
- Negative for HIV-1 and HIV-2 (with a fourth generation enzyme-linked immunosorbent assay (ELISA) assay)
- Willing the geocoding of the postal address and to be contacted via telephone or email, on a regular basis
- Willing to comply to visits schedule (every 3 months)
- Health security program
- Informed consent form signed
High risk of acquiring HIV infection:
For MSM and transgenders:
- Anal sex with at least two different sexual partners and no consistent condom use over the last 6 months
- And/or history of STD during the last 12 months (syphilis, gonorrhea , chlamydiae, HBV or HCV infection)
- And/or history of non-occupational post-exposure prophylaxis (PEP) during the last 12 months
- And/or using psycho-actives drugs during sexual intercourses (cocaine, gammahydroxybutyric acid (GHB), Methylenedioxymethamphetamine (MDMA), mephedrone)
- And/or having an HIV-infected sexual partner with a detectable plasma viral load (> 50 copies (cp)/milliliter (ml))
For heterosexual:
- Sexual intercourse with 1 partner originating from regions with high prevalence of HIV infection (> 1%) (South America, Sub-Saharan Africa, South-East Asia, Eastern Europe, French Guyana) and no consistent condom use
- and/or sex workers
- and/or having a sexual partner who is an intravenous drug users sharing injection material
- and/or having an HIV-infected sexual partner with a detectable plasma viral load (> 50 cp/ml)
Exclusion Criteria:
- Stable and exclusive relationship with an HIV-negative partner, or with an HIV-positive partner on antiretroviral therapy (ART) with a plasma viral load < 50 cp/ml
- Positive HIV infection
- Clinical signs of positive HIV infection
- Consistent condom use during sexual intercourse
- Expected trip abroad for 3 consecutive months
- Creatinine clearance lower than 50ml/min
- History of chronic renal disease, osteoporosis or osteopenia
- Receiving an investigational drug
- Receiving or will receive potentially nephrotoxic treatments
- Gastro-intestinal condition that could limit drug absorption
- Potentially non compliant participants
- Breastfeeding
- Hypersensitivity to TDF/FTC
- Positive HBs antigen or isolated anti hepatitis B core (HBc) antibodies if not willing to take daily PrEP
- Severe condition (lymphoma, other cancers, cardio-vascular disease, end-stage renal failure, uncontrolled diabetes)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: PrEP with Truvada®
On demand PrEP (only for MSM - with the possibility of dosing schedule switching): 2 pills of Truvada within 24 to 2 hours prior first sexual intercourse, then 1 pill every 24 hours during the period of sexual activity with one pill after the last sexual intercourse, and one last pill 24 hours later Continuous PrEP: 1 pill every 24 hours, at least 7 days before the first sexual intercourse. When PrEP is to be discontinued, 2 pills 24 hours apart after the last sexual intercourse then stop PrEP. If PrEP is to be resumed, 1 pill every 24 hours, started at least 7 days before the first sexual intercourse or 2 pills at least 2 hours before the first sexual intercourse and then 1 pill every 24 hours. |
Associated with:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of new HIV diagnosis
Time Frame: three years
|
Number of new HIV infections
|
three years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of recent infections
Time Frame: three years
|
Impact of the study on the total number and on recent HIV infections in Île-de- France, and in each key subgroup
|
three years
|
Prevalence of HIV-infection at the screening visit (undiagnosed epidemic)
Time Frame: two years
|
Number of HIV-infected persons at screening visit
|
two years
|
Incidence of HIV infection
Time Frame: three years
|
Incidence of HIV infection in Paris and in the Île-de-France area according to back-calculation approach, and by key subgroups (MSM, transgenders, migrants, etc.)
|
three years
|
Retention in the study
Time Frame: two years
|
Retention in the study, reasons for consent withdrawal
|
two years
|
Counselling
Time Frame: three years
|
Impact of a less intense counselling than the one provided in the ANRS IPERGAY trial, on adherence and efficacy of PrEP
|
three years
|
Type of counselling
Time Frame: three years
|
Impact of counselling according to the type of counselling provided: communautary-based or educational
|
three years
|
Post-exposure prophylaxis
Time Frame: three years
|
Evaluate the participants' need for post-exposure prophylaxis during the course of the study
|
three years
|
Adherence to PrEP
Time Frame: three years
|
Evaluation of adherence by self-administered online questionnaires on last sexual intercourse
|
three years
|
PrEP dosing schedule
Time Frame: three years
|
Assessment of the PrEP dosing schedule used by MSM participants (daily or intermittent) throughout the course of the study
|
three years
|
Safety and tolerability
Time Frame: three years
|
Assessment of PrEP tolerability and safety particularly: incidence of drug-related adverse events, incidence of grade 3-4 adverse events, incidence of adverse events leading to PrEP discontinuation
|
three years
|
Incident HIV infections
Time Frame: three years
|
Comprehensive study of incident HIV infections in those on PrEP Incidence of HIV-infection on PrEP
|
three years
|
Participants Behavior
Time Frame: three years
|
Acceptability of PrEP (including those who will decline participation in the study) and during the course of the study. Impact of PrEP, within a comprehensive prevention offer, on sexual behavior of the participants throughout follow-up
|
three years
|
Integration of PrEP in the daily routine of participants
Time Frame: three years
|
|
three years
|
Care Providers Behavior
Time Frame: three years
|
Evaluation of knowledge, beliefs, perception and practice of the physicians, nurse and peer counselors involved in delivery of PrEP in the study
|
three years
|
Social epidemiology
Time Frame: three years
|
|
three years
|
Cost-effectiveness
Time Frame: three years
|
Cost-effectiveness of the comprehensive prevention strategy provided in this study
|
three years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jean-Michel MOLINA, Pr, Hôpital Saint Louis, Paris, FRANCE
- Study Chair: Jade GHOSN, MD, Hôpital Hôtel-Dieu, Paris, FRANCE
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
- Emtricitabine
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Other Study ID Numbers
- ANRS PREVENIR
- 2016-A01577-44 (REGISTRY: French Drug Regulatory Authorities Clinical Trial System)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
Clinical Trials on PrEP with Truvada®
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
IpsenCompletedDigestive System DiseaseCzechia, France, Germany, Poland, Netherlands, Italy
-
NorgineCompletedHealthy | Gastric EmptyingUnited Kingdom
-
Queen Elizabeth Hospital, Hong KongRecruitingBowel Preparation Solutions | ColonoscopyHong Kong
-
University of LiegeUnknown
-
HIV Prevention Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Division of...Enrolling by invitationHIV Infection | Sexually Transmitted Infections | Pre-exposure Prophylaxis | Systems NavigationMalawi
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV InfectionUnited States
-
University of Colorado, DenverGilead SciencesCompletedHIV Infections | Sexually Transmitted InfectionsUnited States
-
Children's National Research InstituteAmerican Diabetes AssociationActive, not recruitingType 1 Diabetes MellitusUnited States
-
University of WashingtonBill and Melinda Gates FoundationCompleted